Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2021 02:00 ET | Source: Oxurion NV

OXURION to Participate in Upcoming Investor Meetings

Leuven, BE, Boston, MA, US – March 8, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, with a...
January 20, 2021 02:00 ET | Source: Oxurion NV

Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer

Leuven, BE and Boston, MA, US - January 20, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies,...
January 07, 2021 02:00 ET | Source: Oxurion NV

OXURION to Participate in Upcoming Investor Meetings

OXURION to Participate in Upcoming Investor Meetings Leuven, BELGIUM, Boston, MA, US - January 7, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing...
November 09, 2020 01:30 ET | Source: Oxurion NV

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices Composition-of-matter patents protect THR-687 until 2039-2044 Leuven, Belgium and Boston, MA, November 9, 2020 –...
October 22, 2020 12:47 ET | Source: Oxurion NV

ONCURIOUS I-O Portfolio Directed at Boosting T Cell Influx and Activity in Solid Tumors Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program

Strategic focus of immuno-oncology (I-O) portfolio on modulation of tumor microenvironment to enhance T cell influx and activity in immune excluded solid tumors, aspects that immune checkpoint...
October 15, 2020 02:00 ET | Source: Oxurion NV

Oxurion NV Business Update – Q3 2020

Oxurion NV Business Update – Q3 2020 Progressing Clinical Development of Next Generation Diabetic Macular Edema (DME) Therapies – Beyond anti-VEGF First Patient dosed in Phase 2 study (‘KALAHARI’)...
October 13, 2020 11:45 ET | Source: Oxurion NV

Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer

Oxurion NV appoints Tom Graney, CFA as Chief Financial Officer Boston-based former Vertex and Generation Bio CFO Brings Significant Operational, US Capital Markets and Investor Relations Expertise ...
October 08, 2020 02:00 ET | Source: Oxurion NV

Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET

Invitation OXURION R&D Investor Day – Virtual 15 October 2020 at 5.30pm CET/ 11.30am ET Leuven, Belgium, October 8, 2020 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical...
October 05, 2020 04:00 ET | Source: Oxurion NV

Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020

SAVE THE DATE: Oxurion to host Virtual R&D Investor Day on 15 October 2020 Leuven, Belgium, October 5, 2020 – 10 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company...
September 29, 2020 02:00 ET | Source: Oxurion NV

Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4

Oxurion NV to Present New Pre-Clinical Data on THR-687 at EURETINA 2020 Virtual Meeting, Oct 2-4 Data confirming the promise of THR-687 in treating DME and other retinal vison-threatening retinal...